Health Science Hub
Health Science Hub

Evidence-Based Reviews & Longevity Research

Could CAR T Cells Reset Rheumatoid Arthritis? The First Trial Offers a Remarkable Early Signal

Health Science Hub Editorial

Evidence review & editorial synthesis

Rheumatoid arthritis is usually managed rather than erased. Modern drugs can suppress inflammation remarkably well, but many patients need ongoing treatment, and a difficult minority cycle through therapy after therapy without adequate control. A new phase 1 trial now raises a much bigger possibility: could a single intensive CAR T-cell treatment reset the faulty immune system deeply enough to produce lasting remission without continued arthritis medication?

In the first prospective rheumatoid arthritis trial of its kind, six people with exceptionally severe, treatment-refractory disease received one infusion of CD19-targeted CAR T cells. All six improved. At their latest follow-up, three had reached DAS28-CRP remission and an ACR70 response, meaning at least 70% improvement across a defined set of disease measures, despite having stopped their disease-modifying rheumatoid arthritis drugs. The study was published in Nature Medicine.

That is not a cure. It is six patients in an uncontrolled phase 1 study. But it represents something more interesting than another modest addition to the rheumatoid arthritis drug cabinet.

From suppressing autoimmunity to trying to reset it

Rheumatoid arthritis develops when immune activity that should protect the body instead contributes to persistent inflammation of the joints. B cells are part of that process. They can produce disease-associated autoantibodies, present antigens and help organize inflammatory immune responses.

Existing therapies can already target B cells. Rituximab, for example, depletes B cells carrying CD20 and is an established option in rheumatoid arthritis. But rheumatoid arthritis treatment is still fundamentally built around sustained disease control. The 2025 EULAR treatment recommendations describe a sequence beginning with conventional disease-modifying therapy and moving to biologic or targeted agents when necessary. Even after sustained remission, complete withdrawal is approached cautiously because disease can flare again.

CAR T cells pursue B-cell depletion much more aggressively. A patient's own T cells are collected and genetically modified so that they recognize CD19, a marker found across a broad range of B cells. After lymphodepleting chemotherapy, the engineered cells are returned to the patient, expand inside the body and hunt their target.

In cancer, that strategy can eliminate malignant B cells hidden in tissues. In autoimmunity, the hope is different: eliminate the B-cell populations sustaining the abnormal immune memory, then allow a healthier B-cell repertoire to rebuild.

That is the revolutionary delta. Instead of repeatedly suppressing the same autoimmune process, researchers are asking whether they can interrupt it deeply enough that the immune system restarts differently.

What happened in the six patients

The participants were not typical rheumatoid arthritis patients. They had severe ACPA-positive disease that remained active despite extensive previous treatment. According to Charité, some had already received as many as eight modern targeted or biologic therapies.

All disease-modifying rheumatoid arthritis treatments were stopped before CAR T-cell therapy. Participants then underwent standard lymphodepletion and received a single infusion of the fully human CD19 CAR T-cell product mivocabtagene autoleucel.

After 36 to 52 weeks of follow-up, disease activity had improved in every participant. The median reduction in DAS28-CRP was 34%. Three of the six reached DAS28-CRP remission and achieved an ACR70 response.

The immune changes were just as intriguing. CD19-positive B cells were depleted not only from the blood but from tissues. Autoantibodies then declined continuously. Four of six participants lost detectable antibodies against mutated citrullinated vimentin, one form of ACPA, and five of six became negative for rheumatoid factor IgM.

That combination matters. A temporary reduction in painful joints would be useful. A simultaneous fall in clinical disease activity, tissue B-cell burden and hallmark autoantibodies is more compatible with the hypothesis that the underlying autoimmune machinery itself is being altered.

The safety signal is encouraging, not settled

CAR T therapy is not a benign injection. Patients first receive chemotherapy to create space for the engineered cells. CAR T cells can then trigger cytokine release syndrome, neurological toxicity, infections and other complications.

In this six-person trial, all participants developed cytokine release syndrome, but events were limited to grade 1 or 2. No immune effector cell-associated neurotoxicity syndrome and no serious adverse events were reported. One participant developed a grade 3 elevation in liver enzymes that resolved without lasting consequences.

For a first phase 1 cohort, that was sufficiently reassuring for investigators to advance the program. But six patients cannot establish the risk profile of a therapy that deliberately and profoundly alters the immune system.

The relevant comparison is also not CAR T therapy versus doing nothing. It is CAR T therapy versus increasingly effective conventional and biologic treatments that are simpler, cheaper and far more extensively studied.

Why this result is bigger than rheumatoid arthritis

The trial did not appear from nowhere. CD19 CAR T-cell therapy has already produced striking responses in small groups of people with other severe autoimmune diseases.

A 2024 New England Journal of Medicine case series followed 15 people with severe lupus, inflammatory myositis or systemic sclerosis after a single CD19 CAR T-cell treatment. Patients showed remission or major clinical responses, and all discontinued immunosuppressive therapy during follow-up. Earlier lupus work had shown that B cells could eventually return without immediately recreating the same autoimmune state.

Rheumatoid arthritis has also provided another clue. A 2024 Nature Medicine study used blinatumomab, a bispecific antibody that recruits a patient's existing T cells to destroy CD19-positive B cells, in six people with multidrug-resistant rheumatoid arthritis. Disease activity declined rapidly and the returning B-cell compartment looked more naive, again pointing toward the possibility of an immune reset rather than simple temporary suppression.

CAR T therapy may therefore be part of a broader transition in autoimmune medicine: from continuously blocking inflammatory pathways toward deliberately rebuilding the immune-cell populations that generate the disease.

The experiment that matters comes next

The next stage of the COMPARE trial is designed to answer a much harder question. CAR T-cell therapy will be compared with rituximab, an established B-cell-depleting treatment. The registered study will examine safety, autoantibody conversion, clinical responses, relapse and drug-free survival over 52 weeks.

That comparison is crucial. If ordinary B-cell depletion produces similar results, the extraordinary complexity of CAR T therapy may offer little practical advantage. If CAR T cells create deeper tissue depletion, more complete autoantibody loss and substantially longer drug-free remission, the argument changes.

The future vision is easy to understand. A person with severe rheumatoid arthritis who currently faces years of escalating medication might instead undergo one intensive treatment, rebuild a less autoreactive B-cell system and spend a prolonged period without active disease or continuous immune suppression.

Medicine cannot offer that future yet. Three drug-free remissions among six exceptionally difficult cases are far too early to rewrite rheumatoid arthritis care. But they are enough to make the central question newly serious.

For the first time in a prospective rheumatoid arthritis trial, CAR T therapy has shown that a deep immune reset may be more than a theoretical ambition.

Scientific References & Further Reading

Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.

Related Research